Empirical Precision Medicine
Transforming the Cancer Care Continuum
Scroll down to learn more
Why this matters
Empirical drug sensitivity data will accelerate the developent of new cancer therapies, increasing clinical effectiveness and reducing costly side effects and overall healthcare costs.
At EMPIRI, our mission is to transform cancer care with empirical, personalized drug response data. Our empirical assessment of individual tumor tissue response to specific cancer therapies will bridge the gap between clinical research and patients, and optimize cancer treatment.
Our pragmatic and clinically validated approach is cancer agnostic and independent of genomic or histologic diagnosis.
Services we provide
EMPIRI provides cutting-edge correlative study services for pharmaceutical research and clinical trials, using E-slice and single cell sequencing technologies.
We provide E-slice analysis using biopsy cores or surgical material to our select partners engaged in clinical trials in the TMC area. We can provide early response data in time to make agile decisions on your trial design and enrollment.
Single Cell Sequencing
We offer end-to-end single cell RNA sequencing service, from tissue dissociation to bioinformatics analysis. We decipher the complexity of each cancer ecosystem through droplet-based single cell RNA sequencing service, including immune profiling.
The vision of our company is to transform the way we treat cancer, and we have set a three phase development roadmap for the upcoming years.
Collaborators and Clients